Literature DB >> 12823359

Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.

E Harris, J Behrens, D Samson, A Rahemtulla, N H Russell, J L Byrne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12823359     DOI： 10.1046/j.1365-2141.2003.04395_2.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

Review 1.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 3.  Advances in treatment for relapses and refractory multiple myeloma.

Authors:  Tiffany Richards; Donna Weber
Journal:  Med Oncol       Date:  2010-03-06       Impact factor: 3.064

Review 4.  Drug-induced hyperkalemia.

Authors:  Chaker Ben Salem; Atef Badreddine; Neila Fathallah; Raoudha Slim; Houssem Hmouda
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

Review 5.  Current Trends of Renal Impairment in Multiple Myeloma.

Authors:  Punit Yadav; Mark Cook; Paul Cockwell
Journal:  Kidney Dis (Basel)       Date:  2016-02-03

Review 6.  The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China.

Authors:  Hao Shi; Zijin Chen; Jingyuan Xie; Nan Chen
Journal:  Kidney Dis (Basel)       Date:  2016-01-21

Review 7.  Kidney disease associated with plasma cell dyscrasias.

Authors:  Eliot C Heher; Nelson B Goes; Thomas R Spitzer; Noopur S Raje; Benjamin D Humphreys; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2010-05-12       Impact factor: 22.113

Review 8.  Kidney disease and multiple myeloma.

Authors:  Eliot C Heher; Helmut G Rennke; Jacob P Laubach; Paul G Richardson
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

9.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 10.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.